Immutrin Raises $87M to Advance Amyloidosis Antibody Therapy
CAMBRIDGE, UK, April 8, 2026 Immutrin Ltd has successfully raised £65 million ($87 million) in an oversubscribed Series A...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
CAMBRIDGE, UK, April 8, 2026 Immutrin Ltd has successfully raised £65 million ($87 million) in an oversubscribed Series A...
Cambridge, Massachusetts, USA / Rotterdam, Netherlands / Shanghai, China | March 22, 2026 Harbour BioMed has announced the online...
